Arash Rezazadeh Kalebasty

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 766 citations · Full text

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 507 citations · Full text

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 393 citations · Full text

Urology, Versus Observation, Genitourinary Cancer +6

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Maha Hussain, Bertrand Tombal, Fred Saad et al. · Journal of Clinical Oncology · 2023 · 196 citations · Full text

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky et al. · Journal of Clinical Oncology · 2022 · 175 citations

Androgen Receptor, Immunology, Protac Degrader +24